Welcome to our dedicated page for ORASURE TECHNOLOGIES SEC filings (Ticker: OSUR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
OraSure Technologies Inc. filings document the regulatory record of a Nasdaq-listed diagnostics and sample management company. Its Form 8-K reports cover quarterly and annual operating results, Regulation FD presentations, business developments, board changes, and material agreements tied to shareholder and governance matters.
OraSure's proxy materials disclose director elections, executive compensation, board committee structure, shareholder voting matters and governance proposals, including matters related to board classification. The filings also identify the company's common stock listing, capital structure, risk and governance disclosures, and formal records for cooperation agreements, director appointments, resignations and investor communications.
OraSure Technologies, Inc. details its diagnostics and sample management business in an annual report for the year ended December 31, 2025. The company develops rapid tests for HIV, hepatitis C, syphilis, Ebola, sickle cell and COVID-19, plus saliva, urine and microbiome collection systems sold globally to clinical, research and commercial customers.
In November 2025 OraSure acquired BioMedomics, adding the SickleSCAN rapid sickle cell test sold outside the U.S. The company is advancing new products, including a rapid molecular self-test for chlamydia and gonorrhea and an at-home Colli-Pee urine collection device for sexually transmitted infections, both with 510(k) submissions filed in December 2025 and under FDA review.
Revenue mix is shifting sharply as InteliSwab COVID-19 test sales fell from $257,493,000 in 2023 to $45,136,000 in 2024 and $620,000 in 2025, while OraQuick HIV revenue declined to $49,802,000 in 2025 and Genomics products to $31,546,000. A single non-commercial customer represented 63% of revenue in 2023, 24% in 2024 and about 3% in 2025, highlighting reduced concentration but significantly lower COVID-related volumes.
OraSure exited its substance abuse testing business, continues to invest in BARDA-supported Ebola and Marburg virus tests, and emphasizes intellectual property protection across its brands and collection technologies. As of December 31, 2025, the company employed 500 people and held an aggregate non‑affiliate market value of $218,472,693 as of June 30, 2025, with 69,126,173 common shares outstanding as of February 28, 2026.
OraSure Technologies, Inc. reported a change on its board of directors. On February 28, 2026, director David J. Shulkin, M.D. informed the board that he will resign as a director, including his role on the Compensation Committee, effective March 2, 2026.
The company stated that Dr. Shulkin’s decision to step down is not due to any dispute or disagreement with the board, the company, or its management. The board expressed its appreciation for his years of service and contributions. The filing was signed by President and Chief Executive Officer Carrie Eglinton Manner.
OraSure Technologies’ Chief Financial Officer Kenneth J. McGrath reported equity award activity in company stock. On March 1 and March 2, he acquired 88,348 and 26,814 shares of common stock at $0.00 per share through grants and settlement of vested performance units and restricted stock. On March 1, 7,639 and 20,745 shares were withheld at $3.0425 per share to cover tax liabilities tied to these vestings, rather than open-market sales. After these transactions, he directly owned 535,241 shares. The newly granted restricted stock is scheduled to vest in three equal annual installments beginning on March 2, 2027, conditioned on his continued service.
OraSure Technologies President & CEO Carrie Eglinton Manner reported equity compensation and related tax withholding transactions in company common stock. On March 2, 2026, she received a grant of 355,464 shares of restricted stock that vest in three equal annual installments beginning March 2, 2027, conditioned on continued service.
On March 1, 2026, she acquired 129,032 shares delivered in settlement of vested performance units and had 56,116 and 122,655 shares withheld at $3.0425 per share to cover tax liabilities tied to vesting of performance units and restricted shares. After these transactions, she directly owned 2,136,552 common shares.
OraSure Technologies reported sharply lower results for the quarter and year ended December 31, 2025 as COVID-related demand faded and core markets softened. Q4 2025 net revenues were $26.8 million, down 29% from $37.4 million a year earlier, and full-year revenues fell to $115.0 million from $185.8 million. The company posted a Q4 GAAP net loss of $19.3 million and a full-year loss of $68.7 million, with Q4 non-GAAP operating loss widening to $15.2 million. Despite the downturn, Q4 non-GAAP gross margin improved to 41.4% and cash and cash equivalents totaled $199 million with no debt.
Core revenues of $26.7 million in Q4 declined 22% year-over-year, driven by a 20% drop in diagnostics sales to $15.1 million and a 39% decline in Sample Management Solutions revenues to $9.1 million. COVID-19 revenues nearly disappeared, falling 95% in Q4 and 99% for the year. Management highlighted cost actions, site consolidations, product line closures, and a $40 million share repurchase program, of which $5 million was used in Q4 to buy back about 1.9 million shares. Looking ahead, the company is guiding Q1 2026 total revenues to $26–29 million and expects low‑40% non-GAAP gross margins, while banking on potential FDA clearances for a rapid molecular self‑test for chlamydia and gonorrhea and the Colli‑Pee urine collection device to help return the business to growth.
Orasure Technologies, Inc. shareholder Neil Gagnon, together with affiliated advisers Gagnon Securities LLC and Gagnon Advisors, LLC, filed an amended Schedule 13G reporting beneficial ownership of the company’s common stock. Neil Gagnon is deemed to beneficially own 3,565,315 shares, or 4.9% of the common stock, including shares over which he has both sole and shared voting and dispositive power. The ownership percentages are calculated based on 71,733,530 shares outstanding as of October 31, 2025. The filing certifies that the securities are not held to change or influence control of Orasure Technologies.
Altai Capital Management, which reports owning approximately 5.2% of OraSure Technologies’ common stock, has launched an activist campaign to change the Company’s Board. Altai has filed a proxy solicitation seeking to elect two nominees, John Bertrand and Altai founder Rishi Bajaj, at OraSure’s 2026 Annual Meeting of Stockholders.
Altai states that it is dissatisfied with what it views as OraSure’s share price underperformance and the Board’s strategic and capital allocation decisions, and argues that new directors are needed to improve long-term value. Mr. Bajaj brings public company board and investment management experience, while Mr. Bertrand brings operating and board experience in healthcare technology and artificial intelligence.
OraSure Technologies Inc. is the subject of an amended beneficial ownership filing by Altai Capital Management and related parties, who report owning 3,740,836 shares of common stock, representing 5.21% of the outstanding class. The reporting persons have shared voting and shared dispositive power over all of these shares and no sole voting or dispositive power.
Through this Amendment No. 2, the group discloses that on January 15, 2026, Osprey notified OraSure that it intends to nominate Rishi Bajaj and John Bertrand for election to the board at the company’s 2026 annual stockholder meeting. Osprey also plans to present a proposal asking the board to declassify itself so that all directors stand for election annually, and the reporting persons state they intend to solicit proxies in support of these director nominees and the declassification proposal.
OraSure Technologies (OSUR) filed its Q3 2025 10‑Q showing lower sales and wider losses. Net revenues were $27.085M (down 32% year over year), driven by declines in HIV diagnostics and Sample Management Solutions, plus the wind‑down of risk assessment testing and sharply lower COVID‑19 demand. Gross margin was 43.5%, slightly above last year on mix and higher non‑product revenue.
The company reported an operating loss of $16.1M and a net loss of $13.712M for the quarter. Research and development rose to $10.106M (up 80%) as clinical trials advanced for the CT/NG test acquired with Sherlock. For the nine months, net revenues were $88.258M (down 41%) with an operating loss of $51.866M.
Cash and cash equivalents were $216.478M at September 30, 2025 after a $51.285M year‑to‑date decrease, including $10.001M used to repurchase shares under a $40.0M authorization. Non‑product revenues increased on funded R&D tied to Sherlock and BARDA contracts. Subsequent to quarter‑end, the company signed an agreement to acquire BioMedomics for an upfront $4.0M in cash, plus contingent consideration.
OraSure Technologies (OSUR) reported that it issued a press release announcing its consolidated financial results for the quarter ended September 30, 2025. The company also furnished that release as Exhibit 99.1.
Management hosted a webcast with analysts and investors on November 5, 2025 to discuss results and business developments, and furnished an investor presentation as Exhibit 99.2. The materials were provided under Items 2.02 and 7.01 and are described as furnished, not filed.